Loading...
Market
Story
GSK and Pfizer to Face 75,000 Zantac Cancer Lawsuits in Delaware, Shares Plunge 10%
Jun 3, 2024, 07:23 AM
GSK and Pfizer are set to face approximately 75,000 lawsuits in Delaware state court over claims that their former heartburn treatment, Zantac, causes cancer. A judge ruled that the evidence supporting these claims can be heard by juries, dismissing GSK's motions to exclude plaintiffs' witnesses. Following the ruling, GSK shares plunged by up to 10%, reflecting investor concerns over the potential impact of the lawsuits on the company.
View original story
Similar markets
0-10 • 25%
11-50 • 25%
51-100 • 25%
More than 100 • 25%
GSK wins • 33%
GSK loses • 33%
Settlement reached • 33%
Less than $1 billion • 33%
$1 billion to $5 billion • 33%
More than $5 billion • 33%
Pharmaceutical companies win • 33%
Plaintiff wins • 33%
Settlement • 34%
No other major lawsuits • 25%
Minor settlements • 25%
Major settlements similar to Zantac • 25%
Litigations lead to trials • 25%
Less than 10 • 25%
10-20 • 25%
21-30 • 25%
More than 30 • 25%
None • 25%
1-10 • 25%
11-20 • 25%
More than 20 • 25%
No new settlements • 25%
1-5 new settlements • 25%
6-10 new settlements • 25%
More than 10 new settlements • 25%
Profit decrease • 50%
Profit increase • 50%